Screener
Eikon Therapeutics, Inc. EIKN Net Interest Income
Net Interest Income at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| General and administrative | 17,290 | 14,796 |
| Total operating expenses | 87,337 | 71,383 |
| Loss from operations | (87,337) | (71,383) |
| Interest income (expense), net | 4,380 | 3,160 |
| Other income (expense), net | (1) | (20) |
| Net loss and comprehensive loss | (82,958) | (68,243) |
| Impact of preferred stock extinguishments and modifications | — | (6,300) |
| Net loss attributable to common stockholders | $(82,958) | $(74,543) |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s net interest income?
- Eikon Therapeutics, Inc. (EIKN) reported net interest income of $4.38M in Q1 2026.
Ask your AI about Eikon Therapeutics, Inc.'s net interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude